SCHEMBL202540

SCHEMBL202540

C[SiH2]CC(OC(=O)c1ccccc1)OC(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.53
TP53 P04637 1/20 0.53
PDCD1 Q15116 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
LMNA P02545 4/20 0.47
F2 P00734 1/20 0.47
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 2/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
POLB P06746 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
SCN1A P35498 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
KMT2A Q03164 3/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459546 0.81 TSHR (0.53) TSHRTP53PDCD1CD274LMNA
SCHEMBL416565 0.81 TSHR (0.57) TSHRTP53PDCD1CD274LMNA
SCHEMBL2013038 0.78 LMNA (0.55) TSHRTP53PDCD1CD274LMNA
SCHEMBL27516477 0.77 TSHR (0.57) TSHRTP53PDCD1CD274LMNA
SCHEMBL27782525 0.76 TSHR (0.52) TSHRTP53PDCD1CD274LMNA
SCHEMBL13335240 0.76 TSHR (0.52) TSHRTP53PDCD1CD274LMNA
SCHEMBL28035571 0.75 MEN1 (0.53) TSHRTP53PDCD1CD274LMNA
SCHEMBL28391084 0.75 TSHR (0.50) TSHRTP53PDCD1CD274LMNA
SCHEMBL10596089 0.74 TSHR (0.53) TSHRTP53PDCD1CD274LMNA
SCHEMBL13700339 0.74 TSHR (0.63) TSHRTP53PDCD1CD274LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088872-B2 Procatalyst composition including silyl ester internal donor and method DOW GLOBAL TECHNOLOGIES LLC (US) 2012-01-03 US claimed
US-20100130709-A1 Procatalyst Composition Including Silyl Ester Internal Donor and Method W. R. GRACE & CO.-CONN. 2010-05-27 US claimed
EP-2350143-B1 PROCATALYST COMPOSITION MULTIPLE INTERNAL DONOR HAVING SILYL ESTER AND METHOD GRACE W R & CO (US) 2016-02-17 EP disclosed
EP-2350144-B1 PROCATALYST COMPOSITION INCLUDING SILYL ESTER INTERNAL DONOR AND METHOD GRACE W R & CO (US) 2015-07-15 EP disclosed
US-8222357-B2 Procatalyst composition with multiple internal donor having silyl ester and method UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC (US) 2012-07-17 US disclosed
US-8088872-B2 Procatalyst composition including silyl ester internal donor and method DOW GLOBAL TECHNOLOGIES LLC (US) 2012-01-03 US disclosed
EP-2350144-A1 PROCATALYST COMPOSITION INCLUDING SILYL ESTER INTERNAL DONOR AND METHOD Dow Global Technologies LLC (US) 2011-08-03 EP disclosed
WO-2010065361-A1 PROCATALYST COMPOSITION INCLUDING SILYL ESTER INTERNAL DONOR AND METHOD DOW GLOBAL TECHNOLOGIES INC. (US) 2010-06-10 WO disclosed
US-20100130710-A1 Procatalyst Composition with Multiple Internal Donor Having Silyl Ester and Method W. R. GRACE & CO.-CONN. 2010-05-27 US disclosed
US-20100130709-A1 Procatalyst Composition Including Silyl Ester Internal Donor and Method W. R. GRACE & CO.-CONN. 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130709-A1 Procatalyst Composition Including Silyl Ester Internal Donor and Method GNE, NANS, ELANE TSHR 4670/4885TP53 4488/4885PDCD1 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.